An Analysis of Kezar Life Sciences Inc. (KZR)’s Potential Price Growth


Kezar Life Sciences Inc.’s recently made public that its 10% Owner Morningside Venture Investment unloaded Company’s shares for reported $0.28 million on Feb 06. In the deal valued at $6.88 per share,40,000 shares were sold. As a result of this transaction, Morningside Venture Investment now holds 5,447,993 shares worth roughly $ 30.78 million.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Then, Morningside Venture Investment sold 25,000 shares, generating $178,650 in total proceeds. Upon selling the shares at $7.15, the 10% Owner now owns 5,487,993 shares.

Before that, Morningside Venture Investment sold 50,000 shares. Kezar Life Sciences Inc. shares valued at $359,500 were divested by the 10% Owner at a price of $7.19 per share. As a result of the transaction, Morningside Venture Investment now holds 5,512,993 shares, worth roughly $31.15 million.

Wells Fargo initiated its Kezar Life Sciences Inc. [KZR] rating to an Overweight in a research note published on Friday, December 08, 2021; the price target was $19. PT values the company’s stock at a premium of 70.26 to its Friday closing price. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in mid July with a ‘”an Outperform”‘ rating. Wells Fargo began covering KZR with “an Outperform” recommendation on July 16, 2018. Jefferies started covering the stock on July 16, 2018. It rated KZR as “a Buy”.

Price Performance Review of KZR

On Friday, Kezar Life Sciences Inc. [NASDAQ:KZR] saw its stock jump 4.15% to $5.65. On the same session, the stock had its day’s lowest price of $5.485, but rose to a high of $5.76. Over the last five days, the stock has lost -8.87%. Kezar Life Sciences Inc. shares have fallen nearly -19.74% since the year began. Nevertheless, the stocks have fallen -60.24% over the past one year. While a 52-week high of $18.55 was reached on 02/03/23, a 52-week low of $4.30 was recorded on 03/02/23. SMA at 50 days reached $6.61, while 200 days put it at $7.68. A total of 0.74 million shares were traded, compared to the trading of 0.78 million shares in the previous session.

Levels Of Support And Resistance For KZR Stock

The 24-hour chart illustrates a support level at 5.50, which if violated will result in even more drops to 5.36. On the upside, there is a resistance level at 5.78. A further resistance level may holdings at 5.91. The Relative Strength Index (RSI) on the 14-day chart is 36.65, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.64, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.33%. Stochastics %K at 10.93% indicates the stock is a buying.

How much short interest is there in Kezar Life Sciences Inc.?

A steep rise in short interest was recorded in Kezar Life Sciences Inc. stocks on Jan 30, 2023, dropping by -1.71 million shares to a total of 4.43 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 6.14 million shares. There was a decline of -38.6%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 7.34% of the overall stock float, the days-to-cover ratio (short ratio) fell to 6.65.

Kezar Life Sciences Inc. [KZR] – Who Are The Largest Shareholders?

In filings from Avidity Partners Management LP, it is revealed that the company now owns 6,782,400 shares, or roughly 9.92% of the outstanding KZR shares. In other words, the investor’s shares have risen by 1,368,000 from its previous 13-F filing of 5414400.0. Additionally, SSgA Funds Management, Inc. increased 20.25% of its stake after which the total value it holdings stand at $30,500,893, while BlackRock Fund Advisors added 16.37% of its stake to hold $27.17 million in the firm. Over the last quarter, Suvretta Capital Management LLC purchased 228,744 shares of Kezar Life Sciences Inc., while Bellevue Asset Management AG bought 0 shares. At present, The Vanguard Group, Inc. is holding 2,943,274 shares valued at $21.1 million. Millennium Management LLC owned 2,896,495 shares of the company at the time of its most recent 13F filing, worth $20.77 million.

According to FactSet, Kezar Life Sciences Inc.’s share price will average $17.25 in the next year, based on opinions of analysts polled by the firm. This is up nearly 213.08 percent from its previous closing price of $5.43. Analysts expect Kezar Life Sciences Inc. stock to reach the higher price of $21.00, while the lowest price estimate is $14.00. However, 6 analysts have rated KZR stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here